Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Consensus Target Price from Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned an average rating of “Buy” from the thirteen brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $89.90.

A number of brokerages have issued reports on JANX. Scotiabank increased their target price on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a report on Wednesday, December 4th. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. BTIG Research lifted their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Stifel Nicolaus upped their target price on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Finally, UBS Group began coverage on Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price target for the company.

Janux Therapeutics Price Performance

Janux Therapeutics stock opened at $40.72 on Wednesday. The stock’s 50 day moving average price is $53.36 and its 200 day moving average price is $48.28. The company has a market cap of $2.14 billion, a PE ratio of -34.80 and a beta of 3.23. Janux Therapeutics has a 1-year low of $7.79 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The firm’s revenue was down 82.6% on a year-over-year basis. On average, equities research analysts anticipate that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the transaction, the chief executive officer now owns 257,054 shares of the company’s stock, valued at approximately $13,263,986.40. This represents a 8.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at $4,507,788.32. The trade was a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 108,334 shares of company stock worth $6,070,020. 29.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank grew its holdings in Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after buying an additional 368 shares during the period. Plato Investment Management Ltd purchased a new stake in Janux Therapeutics in the second quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the period. Avanza Fonder AB acquired a new position in Janux Therapeutics during the fourth quarter worth approximately $139,000. Finally, AQR Capital Management LLC purchased a new position in Janux Therapeutics during the second quarter worth approximately $215,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.